Latest PD-L1 Lung Cancer Data Increases Debate On Biomarker
Executive Summary
Data and filing announcements for Bristol and Merck’s PD-1 inhibitors in lung cancer put PD-L1 inhibitor developers in hot seat and create more debate about strategy and practicality of the PD-L1 biomarker.